Skip to main content
OpenTrials
Completed

NCT Number: NCT00777088

Pipeline for Uncoilable or Failed Aneurysms

To determine the safety and effectiveness of Pipeline Embolization Device for the treatment of uncoilable or failed wide-necked intracranial aneurysms (IA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Institute of Neurosurgery, Budapest, Hungary

Loading trial locations.

About this study

Patients with large or giant aneurysms of the internal carotid artery treated with PED. Angiographic follow-up occurs at 3 and 5 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 21 to 75 years, inclusive
  • Patient has a single target IA in the anterior or posterior circulation that:

a) Is located in the following regions of the internal carotid artery: i. Paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments) ii. Cavernous iii. Petrous

b) Has a neck >4 mm or no discernible neck AND a size (maximum fundus diameter) >10 mm

c) Has a parent vessel with diameter 2.5 - 5.0 mm distal/proximal to the target IA

  • Subject has provided written informed consent using the Institutional Review Board (IRB)-approved consent form
  • Subject has the necessary mental capacity to participate and is willing and able to comply with protocol requirements

Exclusion criteria

  • More than one IA requires treatment in the next 6 months
  • Subarachnoid hemorrhage from target IA in the past 60 days
  • Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days)
  • Irreversible bleeding disorder
  • Platelet count < 100 x 103 cells/mm3 or known platelet dysfunction
  • Inability to tolerate, documented evidence of adverse reaction or contraindication to study medications
  • Stent in place at the target IA
  • Contraindication to CT scan or MRI
  • Allergy to contrast used in angiography that cannot be medically controlled
  • Known severe allergy to platinum or cobalt/chromium alloys
  • Relative contraindication to angiography (e.g., serum creatinine > 2.5 mg/dL)
  • Woman of child-bearing potential who cannot provide a negative pregnancy test
  • Evidence of active infection at the time of treatment
  • Other conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known carotid stenosis)
  • Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments to 180 days
  • Extracranial stenosis greater than 50% in the carotid artery for anterior circulation aneurysms
  • Intracranial stenosis greater than 50% in the treated vessel

Treatment and study plan

Pipeline Embolization Device (PED)

Device

1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach

Primary outcomes

  1. Number of Participants With the Occurrence of Major Ipsilateral Stroke or Neurologic Death and Occurrence of Ipsilateral Stroke or Neurologic Death.

    Time frame: 180-days and 5-years

    The number of participants with occurrence of major ipsilateral stroke or neurologic death after PED placement at 180-days and the occurrence of ipsilateral stroke or neurologic death after Pipeline Embolization Devices (PED) placement at 5-years.

  2. Count of Intracranial Aneurysms (IA) Evaluated as Completely Occluded (100%) Without Major Parent Artery Stenosis.

    Time frame: 180 days

    The count of Intracranial Aneurysms (IA) evaluated as completely occluded (defined as Raymond Grade 1) without major parent artery stenosis at 180 days. The Raymond-Roy Grade scale measures the amount of visual contrast flow throughout the aneurysm anatomy. The Raymond-Roy aneurysm occlusion scale is follows:

    Complete = complete occlusion, no flow of contrast seen in the sac Residual Neck = partial occlusion, some flow, or eddying flow, in the sac Residual Aneurysm = incomplete occlusion, apparent flow into the sac

Secondary outcomes

  1. Count of Intracranial Aneurysms (IA) Evaluated as Completely Occluded (100%) at 1 Year

    Time frame: 1 Year

    The count of Intracranial Aneurysms (IA) Evaluated as Completely Occluded (100%) (defined as Raymond-Roy grade 1) 1 year follow-up visit. The Raymond-Roy Grade scale measures the amount of visual contrast flow throughout the aneurysm anatomy. The Raymond-Roy aneurysm occlusion scale is follows:

    Complete = complete occlusion, no flow of contrast seen in the sac Residual Neck = partial occlusion, some flow, or eddying flow, in the sac Residual Aneurysm = incomplete occlusion, apparent flow into the sac

  2. Count of Intracranial Aneurysms (IA) Evaluated as Completely Occluded (100%) at 3 Year Follow-up

    Time frame: 3 years

    The count of Intracranial Aneurysms (IA) evaluated as completely occluded (100%) (defined as Raymond-Roy grade 1) at 3 year follow-up. The Raymond-Roy Grade scale measures the amount of visual contrast flow throughout the aneurysm anatomy. The Raymond-Roy aneurysm occlusion scale is follows:

    Complete = complete occlusion, no flow of contrast seen in the sac Residual Neck = partial occlusion, some flow, or eddying flow, in the sac Residual Aneurysm = incomplete occlusion, apparent flow into the sac

  3. Count of Intracranial Aneurysms (IA) Evaluated as Completely Occluded (100%) at 5 Years

    Time frame: 5 years

    The count of Intracranial Aneurysms (IA) evaluated as completely occluded (100%) (defined as Raymond-Roy grade 1) at 5-year follow-up. The Raymond-Roy Grade scale measures the amount of visual contrast flow throughout the aneurysm anatomy. The Raymond-Roy aneurysm occlusion scale is follows:

    Complete = complete occlusion, no flow of contrast seen in the sac Residual Neck = partial occlusion, some flow, or eddying flow, in the sac Residual Aneurysm = incomplete occlusion, apparent flow into the sac

  4. Stenosis of the Parent Artery in PED at 3 Years

    Time frame: 3-years

    Parent artery stenosis (narrowing of the artery from which the aneurysm arises) at 3-year follow-up

  5. Stenosis of the Parent Artery in PED at 5 Years

    Time frame: 5-years

    Parent artery stenosis at 5-year follow-up

  6. Number of Participants With Device-Related Adverse Events at 3 Years

    Time frame: 3 years

    Number of participants with incidence of device-related adverse events at 3 year follow-up

  7. Number of Participants With Device-related Adverse Events at 5 Years

    Time frame: 5 years

    Subjects Observed with Device Related Adverse Events 5 years after Pipeline Placement

Sponsors and collaborators

Lead sponsor

Medtronic Neurovascular Clinical Affairs

Industry

Registry information

Acronym: PUFS

Important dates

Study start
2008
Primary completion
2014
Study completion
2014
First posted
Oct 22, 2008
Registry last updated
Nov 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.